{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T07:34:55Z","timestamp":1789457695792,"version":"build-2803163510"},"reference-count":47,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2002,10,31]],"date-time":"2002-10-31T00:00:00Z","timestamp":1036022400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2002,11,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>The prevalence of BRCA1 germline mutations is greater in the Ashkenazi Jewish population than in the general North American population. The Ontario Familial Breast Cancer Registry collects clinical and family history data in familial breast carcinoma cases, and unselected Ashkenazi breast carcinomas, and acts as a tumor tissue repository.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>Using this resource, we examined the tumor morphology, hormone receptor status, and HER\u20102\/<jats:italic>neu<\/jats:italic> protein overexpression in Canadian Ashkenazi breast carcinoma patients whose germline BRCA1 mutation status is known.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>Thirty\u2010eight tumors from 32 BRCA1 carriers and 354 tumors from 334 noncarriers were analyzed.The tumors in BRCA1 mutation carriers were more likely to be high grade (<jats:italic>P<\/jats:italic> &lt; 0.0001) and estrogen receptor negative (<jats:italic>P<\/jats:italic> &lt; 0.004). There was an increased frequency of typical medullary carcinomas in mutation carriers when all tumors were analyzed. However, this difference did not remain statistically significant when only the first tumor diagnosed in each patient was included in the analysis. There was no difference in HER\u20102\/<jats:italic>neu<\/jats:italic> protein overexpression between the two groups overall (<jats:italic>P<\/jats:italic> = 0.07). However, when the analysis was restricted to Grade III tumors, there were significantly fewer HER\u20102\/<jats:italic>neu<\/jats:italic>\u2010positive tumors in the mutation carriers versus noncarriers (3.1% vs. 21.5%, <jats:italic>P<\/jats:italic> = 0.012). No significant differences were found in the incidence of lymph node status, progesterone receptor status, lymphatic vessel invasion, degree of lymphocytic infiltration, or in the presence of ductal carcinoma in situ associated with the invasive tumors.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>Increasing awareness of the morphologic and immunophenotypic features more commonly found in BRCA1\u2010associated breast carcinomas may lead to a wider use of these characteristics in genetic screening programs and provide further clues to their pathogenesis. Cancer 2002;95:2068\u201375. \u00a9 2002 American Cancer Society.<\/jats:p><jats:p>DOI 10.1002\/cncr.10949<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.10949","type":"journal-article","created":{"date-parts":[[2002,11,1]],"date-time":"2002-11-01T09:14:49Z","timestamp":1036142089000},"page":"2068-2075","source":"Crossref","is-referenced-by-count":50,"title":["HER\u20102\/<i>neu<\/i> status and tumor morphology of invasive breast carcinomas in Ashkenazi women with known BRCA1 mutation status in the Ontario Familial Breast Cancer Registry"],"prefix":"10.1002","volume":"95","author":[{"given":"Louise A.","family":"Quenneville","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly\u2010Anne","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilmi","family":"Ozcelik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert K.","family":"Parkes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia A.","family":"Knight","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela J.","family":"Goodwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene L.","family":"Andrulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances P.","family":"O'Malley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2002,10,31]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.2000.1407"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/ng1096-185"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/ng1095-198"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20010715)92:2<440::AID-CNCR1340>3.0.CO;2-O"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19970801)80:3<435::AID-CNCR11>3.0.CO;2-Y"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/91.14.1241"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.24.4045"},{"key":"e_1_2_6_9_2","first-page":"369","article-title":"Risk factors for detecting germline BRCA1 and BRCA2 founder mutations in Ashkenazi Jewish women with breast or ovarian cancer","volume":"36","author":"Hodgson SV","year":"1999","journal-title":"J Med Genet."},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/91.24.2112"},{"key":"e_1_2_6_11_2","first-page":"505","article-title":"The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early\u2010onset breast cancer patients among Ashkenazi women","volume":"60","author":"Abeliovich D","year":"1997","journal-title":"Am J Hum Genet."},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19960215)77:4<697::AID-CNCR16>3.0.CO;2-W"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)10109-4"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19981201)83:11<2335::AID-CNCR13>3.0.CO;2-N"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19990621)84:3<263::AID-IJC11>3.0.CO;2-G"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(97)89007-7"},{"key":"e_1_2_6_17_2","first-page":"1839","article-title":"BRCA\u2010associated breast cancer: absence of a characteristic immunophenotype","volume":"58","author":"Robson M","year":"1998","journal-title":"Cancer Res."},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s004390050212"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2559.1991.tb00229.x"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/85.3.200"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1309\/VP4W-5C55-7M09-6TX3"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.5.1642"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(00)00287-2"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19980729)77:3<354::AID-IJC8>3.0.CO;2-N"},{"key":"e_1_2_6_25_2","first-page":"1937","article-title":"Breast tumor immunophenotype of BRCA1\u2010mutation carriers is influenced by age at diagnosis","volume":"7","author":"Vaziri SA","year":"2001","journal-title":"Clin Cancer Res."},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.2001.2103"},{"key":"e_1_2_6_27_2","first-page":"2011","article-title":"Distinct molecular pathogeneses of early\u2010onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population\u2010based study","volume":"59","author":"Armes JE","year":"1999","journal-title":"Cancer Res."},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.19.3360"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.24.4053"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/91.5.469"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/90.15.1138"},{"key":"e_1_2_6_32_2","first-page":"1588","article-title":"Mutations at BRCA1: the medullary breast carcinoma revisited","volume":"58","author":"Eisinger F","year":"1998","journal-title":"Cancer Res."},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0046-8177(98)90427-0"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.1341"},{"key":"e_1_2_6_35_2","first-page":"113S","article-title":"Are BRCA1\u2010 and BRCA2\u2010associated breast cancers different? Prognosis of BRCA1\u2010associated breast cancer","volume":"18","author":"Robson M","year":"2000","journal-title":"J Clin Oncol."},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/91.10.882"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197710)40:4<1365::AID-CNCR2820400402>3.0.CO;2-N"},{"key":"e_1_2_6_38_2","first-page":"782","article-title":"The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2","volume":"6","author":"Lakhani SR","year":"2000","journal-title":"Clin Cancer Res."},{"key":"e_1_2_6_39_2","first-page":"1739","article-title":"Pathological features and BRCA1 mutation screening in premenopausal breast cancer patients","volume":"7","author":"Chang J","year":"2001","journal-title":"Clin Cancer Res."},{"key":"e_1_2_6_40_2","first-page":"1206","article-title":"Major improvement in the efficacy of BRCA1 mutation screening using morphoclinical features of breast cancer","volume":"60","author":"Lidereau R","year":"2000","journal-title":"Cancer Res."},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-2264(200002)27:2<130::AID-GCC3>3.0.CO;2-U"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)03258-X"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.286.18.2251"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008340723974"},{"key":"e_1_2_6_45_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19980715)83:2<310::AID-CNCR15>3.0.CO;2-W"},{"key":"e_1_2_6_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)07065-7"},{"key":"e_1_2_6_47_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1006350518190"},{"key":"e_1_2_6_48_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.2.397"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.10949","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.10949","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T16:43:07Z","timestamp":1760287387000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.10949"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,10,31]]},"references-count":47,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2002,11,15]]}},"alternative-id":["10.1002\/cncr.10949"],"URL":"https:\/\/doi.org\/10.1002\/cncr.10949","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,10,31]]}}}